An evaluation of the efficacy and safety of meprobamate in combination analgesics and the likely economic impact of its withdrawal
| dc.contributor.author | Peter, Amanda, Clare | |
| dc.date.accessioned | 2018-06-08T09:30:08Z | |
| dc.date.available | 2018-06-08T09:30:08Z | |
| dc.date.issued | 2002 | |
| dc.description | A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfilment of the requirements for the degree of Master of Science ( Medicine ) in pharmaceutical affairs Johannesburg | en_ZA |
| dc.description.abstract | South Africa has the highest number of registered medicine containing meprobamate in combination analgesics and is the only country that markets a combination that includes paracetamol, caffeine and codeine. In November 1998 the \medicine Control Council issued a circular (11/98) to the pharmaceutical industry requesting evidence that meprobamate contributes meaningfully to the therapeutic effect in combination analgesics and asked for comment on the risk-benefit ratio | en_ZA |
| dc.description.librarian | IT2018 | en_ZA |
| dc.identifier.uri | https://hdl.handle.net/10539/24633 | |
| dc.language.iso | en | en_ZA |
| dc.subject | economic factor | |
| dc.subject | profit | |
| dc.subject.mesh | Meprobamate | |
| dc.subject.mesh | Analgesics | |
| dc.title | An evaluation of the efficacy and safety of meprobamate in combination analgesics and the likely economic impact of its withdrawal | en_ZA |
| dc.type | Thesis | en_ZA |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Amanda Clare Peter (1).pdf
- Size:
- 3.46 MB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: